$IART News

Integra LifeSciences Holdings (IART) Returns To Profit As Fair Value Debate Stays In Focus

Why Integra LifeSciences (IART) Trimmed Its 2026 Outlook After Returning to Profitability

IART Q2 Deep Dive: Flat Revenue, Margin Pressure, and Operational Realignment Shape Outlook

Integra LifeSciences Holdings Corporation 2026 Q2 - Results - Earnings Call Presentation

Why Integra LifeSciences (IART) Shares Are Sliding Today

Wells Fargo Maintains Equal-Weight on Integra Lifesciences, Raises Price Target to $18

Integra LifeSciences Holdings Corporation (IART) Q2 2026 Earnings Call Transcript

Integra LifeSciences Q2 Earnings Call Highlights

Integra (IART) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Integra LifeSciences (IART) Q2 Earnings Top Estimates

Integra LifeSciences (NASDAQ:IART) Surges Over 30% on Q2 Earnings Beat

Integra LifeSciences’s (NASDAQ:IART) Q2 CY2026 Earnings Results: Revenue In Line With Expectations

Integra LifeSciences Reports Second Quarter 2026 Financial Results

Integra Lifesciences Sees Q3 Adj EPS $0.53-$0.61 vs $0.56 Est; Sees Sales $410.000M-$425.000M vs $418.100M Est

Integra Lifesciences Affirms FY2026 Adj EPS Guidance of $2.40-$2.50 vs $2.45 Est; Lowers FY2026 Sales Guidance from $1.662B-$1.702B to $1.654B-$1.695B vs $1.676B Est

Integra Lifesciences Q2 Adj. EPS $0.56 Beats $0.48 Estimate, Sales $418.761M Beat $418.647M Estimate

UBS Initiates Coverage On Integra Lifesciences with Neutral Rating, Announces Price Target of $19

Integra LifeSciences (IART) To Report Earnings Tomorrow: Here Is What To Expect

IART vs. SONVY: Which Stock Is the Better Value Option?

How Integra LifeSciences’ Earnings Outperformance Track Record At Integra LifeSciences Holdings (IART) Has Changed Its Investment Story